Monthly research recap
Serotonin research: July 2026
What July 2026's 23 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 23 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in July 2026 focused on the mechanisms and therapeutic potential of psychedelics, particularly psilocybin, which was shown to act through 5-HT2A receptors to induce dendritic signaling and plasticity in a brain-state- and sex-dependent manner. Reviews and preclinical studies consistently supported psilocybin's promise for depression and other conditions, but evidence for direct clinical efficacy remained preliminary, with safety concerns and long-term effects still requiring further investigation.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors 2026 | experimental study | Supports | Psilocybin transiently increased dendritic calcium event rates in apical tufts in a brain state- and 5-HT2A receptor-dependent manner, and altered the predictive relationship between acute dendritic calcium signaling and subsequent spine formation. | |
| Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia 2026 | experimental study using knockout mouse model | Mixed | Disrupted mGlu5 signaling amplified acute responses to psilocybin and revealed a sex-dependent long-term effect on sensorimotor gating, with female knockout mice showing sustained normalization in prepulse inhibition nine days after treatment. | |
| Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression 2026 | review | Supports | Ketamine and esketamine have the strongest evidence among rapid-acting antidepressant interventions for treatment-resistant depression, while psilocybin-assisted therapy shows promise but remains investigational. | |
| Integrated 5-HT2A-TrkB and G protein signaling in serotonergic psychedelic responses. 2026 | in vitro study | Supports | Serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network with distinct structural, transcriptional, and metabolic outputs, and TrkB silencing abolished dendritogenic responses. | |
| Sex-dependent effects of psychedelics: review of evidence from rodent models 2026 | review | Supports | Sex is a critical biological variable shaping the neural, physiological, and behavioral effects of classic psychedelics in rodents, with females often showing stronger or qualitatively distinct responses. | |
| Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5-HT2A receptor. 2026 | in vitro study | Supports | Most synthetic cathinones inhibited DAT at nanomolar concentrations, with N-pyrrolidine cathinones with methylenedioxy groups showing the highest DAT potency, suggesting high abuse potential based on DAT/SERT selectivity. | |
| Antidepressant effect of psychedelic compounds and mechanisms underlying the G protein-coupled receptors activation psychedelics: Antidepressant action and GPCR signaling. 2026 | review | Supports | Psychedelics, predominantly through 5-HT2A receptor activation and downstream signaling cascades, produce rapid and sustained antidepressant effects by promoting neuroplasticity and remodeling neural circuits. | |
| Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms 2026 | review | Supports | Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression, indicating a convergence toward scalable and safer neuropsychiatric therapies. | |
| Psychedelic-Assisted Psychosexual Therapy 2026 | review | Supports | Proposes that classic serotonergic psychedelics, empathogenic-entactogenic agents, and glutamatergic dissociatives can enable direct engagement with traumatic, shame-laden, and affective antecedents of sexual difficulties by transiently altering states of consciousness and softening defensive avoidance. | |
| Study 35070 | in vitro experimental study | Supports | Brief 24-hour DMT exposure increases proliferation of human neural stem cells in a concentration-dependent manner and upregulates neurotrophin expression, including BDNF. | |
| Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol. 2026 | scoping review | Supports | Psilocybin shows potential as an alternative pharmacological strategy for OCD, especially for treatment-resistant patients, but systematic evidence mapping is needed. | |
| Psychedelics and the thalamocortical system: A scoping review 2026 | scoping review | Supports | Psychedelics affect thalamocortical connectivity, which may be important for clinical practice and understanding psychedelic neurobiology. | |
| Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data 2026 | observational cohort with re-analysis of multi-centre PET data | 42 | Supports | Large increases in 5-HT1BR binding were observed following both ketamine (6.4%) and ECT (9.3%), with changes distinguishable from placebo, but not associated with individual symptom improvement. |
| α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice. 2026 | preclinical experimental study | Mixed | Activation of the noradrenergic alpha-2 receptor suppresses serotonin 2A receptor-mediated head-twitch responses without blocking antidepressant-like effects in mice. | |
| What are the risks of serotonin syndrome when using MDMA and SSRIs together? 2026 | review | Supports | Combined use of MDMA and SSRIs may increase the risk of serotonin syndrome. | |
| Psilocibin: Current Evidence, Safety Signals, and Challenges in Assessing Potential Multi-Organ Effects 2026 | narrative review | Mixed | Current evidence does not confirm clinically meaningful intrinsic multi-organ toxicity of psilocybin under controlled conditions, but potential safety signals warrant further systematic evaluation. | |
| Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review 2026 | review | Supports | Psilocybin from Psilocybe cubensis mushrooms shows therapeutic potential for depression with sustainable symptom relief and fewer side effects than conventional treatments. | |
| Novel 6,5-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches 2026 | theoretical | Supports | Argues that novel 6,5-bicyclic compounds as 5-HT2A receptor agonists can be used in treating depression, anxiety, substance abuse, and headaches. | |
| Ligand-specific effects of 5-HT2A receptor antagonists on fear extinction in C57BL/6J mice: Comparative insights from MDL 11,939 and MDL 100,907 2026 | experimental study | Mixed | Repeated administration of the mixed 5-HT2A/2C antagonist MDL 11,939 impaired fear extinction in mice, while the selective 5-HT2A antagonist MDL 100,907 and the selective 5-HT2C antagonist SB 242084 did not significantly alter extinction learning. | |
| 5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation. 2026 | experimental study | Supports | 4-AcO-DMT suppresses innate fear responses in rats by activating 5-HT₂A receptors, which engage VIP interneurons in the prelimbic cortex. | |
| MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics. 2026 | computational study | Supports | The 5-HT2A receptor complexes with serotonin, psilocybin/psilocin, LSD, and lumateperone show total interaction energies from -35.38 to -71.98 kcal/mol, with Asp155, Phe339, Leu229, and Val366 being the main stabilizing residues. | |
| Single Ayahuasca administration attenuates alcohol relapse and associated behavioral, neurochemical, and oxidative alterations in rats 2026 | preclinical study | Supports | A single Ayahuasca administration reduced relapse-like ethanol intake, attenuated anxiety- and depressive-like behaviors, and partially reversed alcohol-induced changes in dopamine, serotonin, BDNF, and oxidative stress markers in a sex- and region-dependent manner. | |
| Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. 2026 | systematic review | 20 | Mixed | Psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, but direct evidence of improved social-cognitive functioning remains limited. |
Points of agreement
- Psychedelics like psilocybin and DMT act through 5-HT2A receptors to promote neuroplasticity, including dendritic spine formation and neurogenesis.
- Psilocybin shows promise as a therapeutic for depression and other psychiatric conditions, though evidence is still preliminary.
- Sex is an important biological variable influencing the effects of psychedelics, with females often showing stronger responses.
- Serotonergic signaling is implicated in the mechanisms of action of various treatments, including ketamine and ECT.
Conflicts
- Some studies report positive effects of psychedelics on social cognition, while others find limited direct evidence.
- Findings on the role of 5-HT2A antagonism in fear extinction are mixed, with one antagonist impairing extinction and others not.
- Safety profiles of psilocybin are debated, with some reviews suggesting low toxicity and others highlighting potential risks.
Gaps
- Long-term durability of psychedelic effects on neuroplasticity and clinical outcomes is not well established.
- Most studies are preclinical or in vitro; clinical evidence remains limited and often from small trials.
- Sex-specific effects are understudied, with many studies not reporting or analyzing sex differences.
- The relationship between acute serotonergic signaling and long-term structural plasticity is not fully understood.
- Safety data for psilocybin and other psychedelics in diverse populations are lacking.